METHODS FOR HIGH-THROUGHPUT COMPARATIVE GENOMICS AND DISTRIBUTED SEQUENCE ANALYSIS

High-throughput sequencing has accelerated applications of genomics throughout the world. The increased production and decentralization of sequencing has also created bottlenecks in computational analysis. In this dissertation, I provide novel computational methods to improve analysis throughput in three areas: whole genome multiple alignment, pan-genome annotation, and bioinformatics workflows. To aid in the study of populations, tools are needed that can quickly compare multiple genome sequences, millions of nucleotides in length. I present a new multiple alignment tool for whole genomes, named Mugsy, that implements a novel method for identifying syntenic regions. Mugsy is computationally efficient, does not require a reference genome, and is robust in identifying a rich complement of genetic variation including duplications, rearrangements, and large-scale gain and loss of sequence in mixtures of draft and completed genome data. Mugsy is evaluated on the alignment of several dozen bacterial chromosomes on a single computer and was the fastest program evaluated for the alignment of assembled human chromosome sequences from four individuals. A distributed version of the algorithm is also described and provides increased processing throughput using multiple CPUs. Numerous individual genomes are sequenced to study diversity, evolution and classify pan-genomes. Pan-genome annotations contain inconsistencies and errors that hinder comparative analysis, even within a single species. I introduce a new tool, Mugsy-Annotator, that identifies orthologs and anomalous gene structure across a pan-genome using whole genome multiple alignments. Identified anomalies include inconsistently located translation initiation sites and disrupted genes due to draft genome sequencing or pseudogenes. An evaluation of pan-genomes indicates that such anomalies are common and alternative annotations suggested by the tool can improve annotation consistency and quality. Finally, I describe the Cloud Virtual Resource, CloVR, a desktop application for automated sequence analysis that improves usability and accessibility of bioinformatics software and cloud computing resources. CloVR is installed on a personal computer as a virtual machine and requires minimal installation, addressing challenges in deploying bioinformatics workflows. CloVR also seamlessly accesses remote cloud computing resources for improved processing throughput. In a case study, I demonstrate the portability and scalability of CloVR and evaluate the costs and resources for microbial sequence analysis

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) : part two

Background The immunological escape of tumors represents one of the main ob- stacles to the treatment of malignancies. The blockade of PD-1 or CTLA-4 receptors represented a milestone in the history of immunotherapy. However, immune checkpoint inhibitors seem to be effective in specific cohorts of patients. It has been proposed that their efficacy relies on the presence of an immunological response. Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would synergize with our oncolytic vaccine platform PeptiCRAd. Methods We used murine B16OVA in vivo tumor models and flow cytometry analysis to investigate the immunological background. Results First, we found that high-burden B16OVA tumors were refractory to combination immunotherapy. However, with a more aggressive schedule, tumors with a lower burden were more susceptible to the combination of PeptiCRAd and PD-L1 blockade. The therapy signifi- cantly increased the median survival of mice (Fig. 7). Interestingly, the reduced growth of contralaterally injected B16F10 cells sug- gested the presence of a long lasting immunological memory also against non-targeted antigens. Concerning the functional state of tumor infiltrating lymphocytes (TILs), we found that all the immune therapies would enhance the percentage of activated (PD-1pos TIM- 3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos TIM-3pos) cells compared to placebo. As expected, we found that PeptiCRAd monotherapy could increase the number of antigen spe- cific CD8+ T cells compared to other treatments. However, only the combination with PD-L1 blockade could significantly increase the ra- tio between activated and exhausted pentamer positive cells (p= 0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could decrease the amount of dysfunctional antigen specific T cells. We ob- served that the anatomical location deeply influenced the state of CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in- creased by 2 fold on TILs compared to splenic and lymphoid T cells. In the CD8+ compartment, the expression of PD-1 on the surface seemed to be restricted to the tumor micro-environment, while CD4 + T cells had a high expression of PD-1 also in lymphoid organs. Interestingly, we found that the levels of PD-1 were significantly higher on CD8+ T cells than on CD4+ T cells into the tumor micro- environment (p < 0.0001). Conclusions In conclusion, we demonstrated that the efficacy of immune check- point inhibitors might be strongly enhanced by their combination with cancer vaccines. PeptiCRAd was able to increase the number of antigen-specific T cells and PD-L1 blockade prevented their exhaus- tion, resulting in long-lasting immunological memory and increased median survival